Sign in Subscribe
Pharmaceutical industry

Global Benign Prostatic Hyperplasia Treatment Market to Grow at a CAGR of 5.6% through 2026

Strategic Insights

— 2 min read

The global benign prostatic hyperplasia (BPH) treatment market reached a value of US$ 10.5 Billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 5.6% during 2021-2026. The market is driven by the increasing prevalence of urological disorders, rising geriatric population, and growing awareness of treatment alternatives. Key companies mentioned in the report include Abbott Laboratories, Allergan Plc (AbbVie Inc.), Asahi Kasei Corporation, and Pfizer Inc.

The BPH treatment market is influenced by various factors, including the development of new surgical procedures such as transurethral resection of the prostate (TURP) and advancements in healthcare infrastructure. Healthcare providers use alpha-blockers to manage BPH by relaxing the prostate muscles and controlling blood pressure. Additionally, rising health consciousness and awareness of available treatment alternatives are contributing to the market growth. In line with this, the report provides a detailed analysis of the market, including key questions, market structure, competitive landscape, and market forecast.

Key Takeaways:

  • The global BPH treatment market reached a value of US$ 10.5 Billion in 2020 and is expected to grow at a CAGR of 5.6% during 2021-2026.
  • The market is driven by the increasing prevalence of urological disorders, rising geriatric population, and growing awareness of treatment alternatives.
  • Key companies mentioned in the report include Abbott Laboratories, Allergan Plc (AbbVie Inc.), Asahi Kasei Corporation, and Pfizer Inc.
  • The market is influenced by factors such as the development of new surgical procedures, advancements in healthcare infrastructure, and growing awareness among the masses.
  • Healthcare providers use alpha-blockers to manage BPH by relaxing the prostate muscles and controlling blood pressure.
  • The market is expected to be driven by the rising health consciousness and awareness among the masses regarding the available treatment alternatives.
  • Transurethral resection of the prostate (TURP) is an effective treatment procedure for BPH.
  • The market is expected to grow due to significant improvements in the healthcare infrastructure, especially in developing countries.
  • The global BPH treatment market is expected to grow at a compound annual growth rate (CAGR) of 5.6% during 2021-2026.

Statistics:

  • The global BPH treatment market reached a value of US$ 10.5 Billion in 2020.
  • The market is expected to grow at a CAGR of 5.6% during 2021-2026.
  • The market is driven by the increasing prevalence of urological disorders, rising geriatric population, and growing awareness of treatment alternatives.

Sources:

  • "Benign Prostatic Hyperplasia Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report by ResearchAndMarkets.com
  • BusinessWire - Global Benign Prostatic Hyperplasia Treatment Market to Grow at a CAGR of 5.6% through 2026

Read more